Showing 4491-4500 of 5627 results for "".
- Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trialhttps://modernod.com/news/graybug-vision-reports-preliminary-topline-results-from-phase-2b-altissimo-trial/2478951/Graybug Vision provided preliminary topline data from the 12-month treatment phase of its phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary microparticle depot formulation of sunitinib malate injected intravitreally. T
- Allergan Launches Glaucoma in Perspective Apphttps://modernod.com/news/allergan-launches-glaucoma-in-perspective-app/2478950/Allergan has announced the launch of Glaucoma in Perspective (GiP), an app designed to help patients understand the impact of glaucoma, improve quality of life, and reduce disease progression by promoting treatment adherence. The GiP app has been produced and funded by Allergan, with consu
- CorNeat Vision Partners with LiveU and Alcon for Remote Surgeon Virtual Presencehttps://modernod.com/news/corneat-vision-partners-with-liveu-and-alcon-for-remote-surgeon-virtual-presence/2478949/CorNeat Vision and LiveU, a provider of live video streaming and remote production solutions, announced that they have partnered and implemented an on-demand Remote Surgeon Virtual Presence (RSVP) solution. The companies cooperated with Alcon to leverage its NGENUITY 3D Visualization Syste
- CooperVision Introduces 2021 Best Practices Honoreeshttps://modernod.com/news/coopervision-introduces-2021-best-practices-honorees/2478943/During a year of unprecedented challenges brought on by the COVID-19 pandemic, eye care practices across the nation have adapted to meet the changing needs of their patients and find ways to not only survive, but thrive. In celebration of 10 such practices, CooperVision announced its 2021 Bes
- UK, Four Other Countries to Fast-Track Vaccines for SARS-CoV-2 Variantshttps://modernod.com/news/uk-four-other-countries-to-fast-track-vaccines-for-sars-cov-2-variants/2478939/A group of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland issued new rules Thursday aimed at speeding up the development of modified COVID-19 vaccines against emerging SAR-CoV-2 strains. The guidance, developed by the UK’s Medicines and Healthcare products
- Retina Consultants of America Continues Growth With Partnership in Kansas and Missourihttps://modernod.com/news/retina-consultants-of-america-continues-growth-with-partnership-in-kansas-and-missouri/2478935/Retina Consultants of America (RCA) announced it has added Retina Associates, P.A. of Kansas City, based in Kansas and Missouri, to its group of practices. Retina Associates, P.A. serves the greater Kansas City, Topeka, Sedalia, and surrounding areas. Terms of the deal were no
- Eyenovia Announces FDA Acceptance of Filing of NDA for MydCombihttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda/2478929/Eyenovia announced that the FDA has accepted the company’s new drug application (NDA) for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic applied with a high precision smart delivery system, the Optejet.
- Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-patient-dosing-in-first-cohort-of-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478927/Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicenter,
- SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Advance Gene Therapieshttps://modernod.com/news/saliogen-therapeutics-announces-closing-of-20-million-series-a-financing-to-advance-gene-therapies/2478925/SalioGen Therapeutics announced that it has closed a $20 million Series A financing to support the preclinical validation of the company’s proprietary Exact DNA Integration Technology (EDIT) platform for the development of durable, safe and affordable in vivo gene the
- J&J’s COVID-19 Vaccine Wins FDA Authorization for Emergency Usehttps://modernod.com/news/jjs-covid-19-vaccine-wins-fda-authorization-for-emergency-use/2478921/The US has added a third option to its arsenal of COVID-19 vaccines after the FDA authorized Johnson & Johnson’s single-dose candidate Ad26.COV2.S for emergency use in people 18 years and older on Saturday. Peter Marks, director of the FDA’s Center for Biologics Evaluation a